All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec005}
============

Cytomegalovirus (CMV) infection is one of the most common complications in solid organ transplant (SOT) patients. Currently, prophylaxis and preemptive treatments have decreased the incidence of disease and death by CMV. However, mutations associated with resistance to antivirals have become an important problem with a high associated morbidity and mortality \[[@pone.0219701.ref001], [@pone.0219701.ref002]\].

In the transplant setting, the incidence of drug resistance mutations (DRM) is 5--12% depending on the group of patients studied but may be higher than 20% in patients with suspected DRM \[[@pone.0219701.ref003], [@pone.0219701.ref004]\].

Diagnostic laboratory testing should be performed whenever there is a criterion of suspicion of resistance since suboptimal response to treatment may have other causes, and inadequate empiric changes in therapy may have adverse effects \[[@pone.0219701.ref005], [@pone.0219701.ref006]\]. Genotypic testing by Sanger sequencing of the protein kinase gene (*UL97*) and DNA polymerase gene (*UL54*) is the usual method for detecting drug resistance and is the basis of the selection of alternative therapy \[[@pone.0219701.ref007]\]. However, Sanger DNA sequencing is unable to detect and quantify subpopulations of viral mutants of less than 20--30%, which may be crucial for selecting the most adequate therapy \[[@pone.0219701.ref008]\].

In the last years next generation sequencing (NGS) technologies have provided better understanding of the complexity of variant populations, increasing the detection of subpopulations of minority variants which have a prevalence of 1--3%. Nevertheless, to date, only a few studies have evaluated CMV DRM using NGS and most of these studies were carried out in a reduced number of patients \[[@pone.0219701.ref009]-- [@pone.0219701.ref012]\].

The present study was conducted within the context of the Group for the Study of Infection in Transplantation (GESITRA), constituting one of its major lines of clinical research. The nationwide network of Spanish hospitals participating in GESITRA has allowed the inclusion of a wide variety of SOT recipients.

The aim of this study was to identify CMV drug resistance mutations in solid organ transplant recipients with suspected resistance comparing NGS with Sanger sequencing and to assessing risk factors and the clinical impact of resistance detected by NGS.

Materials and methods {#sec006}
=====================

Settings and study population {#sec007}
-----------------------------

We conducted a prospective observational study in nine hospitals included in the Spanish Network for Research in Infectious Diseases (REIPI). Adult SOT patients with suspected DRM were included in the study from September 2013 to August 2016. Resistance was suspected when there was persistent or increasing CMV viral load despite ≥ 2 weeks of appropriate antiviral treatment, or failure to have a significant improvement in clinical symptoms despite 2 weeks of full-dose antiviral therapy.\[[@pone.0219701.ref002],[@pone.0219701.ref005],[@pone.0219701.ref006]\]

The coordinating centre was the Hospital Clinic of Barcelona (Spain), which performed the genotypic resistance testing as well as the data analysis. Patient treatment and follow-up were conducted as per the protocol of each centre. All patients were initially treated with standard-dose ganciclovir/valganciclovir (GCV/VGCV) (adjusted to renal function).

Monitoring of CMV viral load was based on local quantitative PCR-based assays. On the suspicion of resistance, plasma samples were collected and frozen at -80°C in the respective hospital and sent in batches to the Microbiology Laboratory of the Hospital Clinic every 4 months. Thus, genotypic testing was not carried out in real time and all patients received empiric treatment on the presence of suspected drug resistance.

Data at patient inclusion and during follow-up were registered in a clinical database at each participating hospital. We reviewed medical histories in terms of viral response, rejection and mortality at 3 months after suspicion of resistance.

The DRM detected by Sanger sequencing and NGS were also included in the database.

CMV infection and disease and acute cellular rejection were defined as described previously \[[@pone.0219701.ref005], [@pone.0219701.ref006]\].

The study was endorsed by Group for the study of Infection in Transplantation (GESITRA) and approved by the Ethical Committee of Hospital Clínic (Comité Ético de Investigación del Hospital Clínic de Barcelona, CEIC), approval number HCB/2012/7598) as the reference committee for the all participating centres according to legal regulations in Spain.

Microbiological studies {#sec008}
-----------------------

In the coordinating laboratory, all samples were kept at -80°C until processing. DNA extraction was performed in 500 μL of each plasma sample using the QIAsymphony system (Qiagen, Hilden, Germany). CMV viral load was confirmed by CMV Real Time PCR (Nanogen Advanced Diagnostics, Italy) according to the manufacturer's instructions.

Subsequently, all samples were analysed by Sanger sequencing based on PCR amplification of the CMV *UL97* protein kinase gene (codons 400--670) in a single fragment and the *UL54* DNA polymerase gene (codons 300--1000) in four fragments \[[@pone.0219701.ref003]\].

Afterwards, antiviral resistance NGS, using Ion Torrent PGM (Ion Personal Genome Machine, Ion Torrent Life Technologies, South San Francisco, CA) was performed by flanking both the *UL97* and *UL54* gene.

Primer and library design for NGS {#sec009}
---------------------------------

To create DNA library, *UL97* and *UL54* primers and PCR conditions previously validated and described by Sahoo MK et al were used \[[@pone.0219701.ref010]\].

After establishing the whole technique, pilot tests were performed in Ion Torrent PGM in order to adjust the reproducibility of the technique. The test of reproducibility was carried out in a total of 6 control samples which included: 2 samples without suspicion of resistance, 2 samples from QCMD with known DRMs, and 2 clinical samples with known DRMs tested by Sanger. The results were the same in two sequencing experiments. Each run had a pool of the 6 samples in 3 different libraries with the same DNA extract. \[[@pone.0219701.ref013]\]

The limit of detection to avoid false positive results was defined as 5% according to Sahoo et al \[[@pone.0219701.ref010]\]

Sequencing and bioinformatic analyses {#sec010}
-------------------------------------

Forty-eight samples were sequenced in the Ion PGMTM 35 System for NGS. Quality assessment of the FASTQ files was performed using FastQC--version 0.11.3 \[[@pone.0219701.ref014]\]. The resulting reads were aligned to the human herpesvirus 5 strain Merlin reference genome (GenBank: AY446894.2) using the BWA-MEM algorithm from BWA version 0.7.12 with default parameters \[[@pone.0219701.ref015]\]. Alignments were sorted and indexed using Sambamba version 0.5.1 \[[@pone.0219701.ref016]\]. Duplicate reads in sorted BAM files were identified and removed using Picard tools \[[@pone.0219701.ref017]\]. GATK base quality score recalibration, insertion and delection (INDEL) realignment, and duplicate removal were applied \[[@pone.0219701.ref018]\]. The discovery of single nucleotide polymorphisms (SNP) and INDEL and genotyping were simultaneously performed across 12 samples to optimise this method using standard filtering and variant quality score recalibration according to the GATK Best Practices recommendations \[[@pone.0219701.ref019]\]. Genetic variant annotation and prediction of the effects of variants on genes (such as amino acid changes) were done using snpEff \[[@pone.0219701.ref020]\]. To do this a snpEff database was created using the information of the reference genome provided by GenBank. The resulting variant call format (VCF) files were post-processed with in-house R \[[@pone.0219701.ref021]\] scripts using Bioconductor packages \[[@pone.0219701.ref022]\] to identify mutations by gene (i.e. *UL54* and *UL97*) in order to find the relative position of each mutation to the first position of the corresponding gene and to filter mutations by missing calls by depth at a sample level (DP\> = 5), by allele depth (AD\> = 5), and by poor quality calls (in which the percentile of minimum quality accepted was 5%).

An average 247382 raw sequences per sample were obtained in the samples sequenced in this study. After pipeline passing quality filters 142.078 reads were obtained per sample.The mean coverage among the different amplicons was up to 2000X

Statistical analysis {#sec011}
--------------------

A database was developed for the registry of the patients enrolled in Open Clinica 3.1 \[GNULesser General Public License (GNU LGPL)\].

Categorical variables are expressed as number and percentage of patients, and the median (interquartile range \[IQR\]) is used for continuous variables with a non-normal distribution and the mean (standard deviation \[SD\]) for those with a normal distribution. Categorical variables were compared using the X^2^ test or the Fisher exact test. Continuous variables were compared using the *t* test or the non-parametric Mann-Whitney test. Logistic regression analyses were performed to identify variables associated with the presence of mutations. Variables showing a significant result in the univariate analyses (p\<0.05) were included in the multivariate model (forward stepwise procedure). The Hosmer-Lemeshow goodness-of-fit test was performed to assess the overall fit of the models \[[@pone.0219701.ref023]\]. The area under the receiver operating characteristic (ROC) curve of the multivariate model to predict the presence of mutations was calculated. Internal validation of the prediction model was conducted using ordinary nonparametric bootstrapping with 1,000 bootstrap samples and bias-corrected, accelerated 95% CIs \[[@pone.0219701.ref024]\] ([S1 Text](#pone.0219701.s001){ref-type="supplementary-material"}; [S1 Table](#pone.0219701.s004){ref-type="supplementary-material"}). The level of significance was set at 0.05 (2-tailed). All analyses were performed using IBM SPSS Statistics 22.0 (Armonk, New York, USA).

Results {#sec012}
-------

During the study period, 48 adults who had undergone SOT and in whom CMV antiviral resistance was suspected were included in the study. Four samples with a low CMV viral load (\< 1.000 copies/ml) were excluded from the analysis because neither Sanger sequencing nor NGS could be carried out. Therefore, 44 patients were finally included. The baseline characteristics of the study population are shown in [Table 1](#pone.0219701.t001){ref-type="table"}.

10.1371/journal.pone.0219701.t001

###### Comparison of the clinical characteristics of the study population at baseline.

![](pone.0219701.t001){#pone.0219701.t001g}

  Variables                                                                          Overall       Without Mutations   With Mutations   P value
  ---------------------------------------------------------------------------------- ------------- ------------------- ---------------- ---------
  **Age, mean (SD), years**                                                          52.5 (12.3)   54.1 (11.8)         49.8 (12.9)      0.26
  **Male sex, n (%)**                                                                32 (72.7)     22 (78.6)           10 (62.5)        0.30
  **Type of transplant, n (%)**                                                                                                         0.24
      Kidney                                                                         19 (43.2)     13 (46.4)           6 (37.5)         0.57
      Liver                                                                          9 (20.5)      6 (21.4)            3 (18.8)         \>0·99
      Heart                                                                          8 (18.2)      5 (17.9)            3 (18.8)         \>0.99
      Lung                                                                           5 (11.4)      1 (3.6)             4 (25.0)         0.050
      Kidney-pancreas                                                                3 (6.8)       3 (10.7)            0 (0)            0.29
  **CMV serostatus, n (%)**[^**a**^](#t001fn002){ref-type="table-fn"}                                                                   0.21
      D+/R-                                                                          26 (61.9)     14 (53.8)           12 (75.0)        0.17
      D+/R+                                                                          13 (31.0)     10 (38.5)           3 (18.8)         0.30
      D-/R+                                                                          2 (4.8)       2 (7.7)             0 (0)            0.52
      D-/R-                                                                          1 (2.4)       0 (0)               1 (6.3)          0.38
  **Induction therapy, n (%)**                                                                                                          
      Basiliximab                                                                    21 (47.7)     16 (57.1)           5 (31.3)         0.098
      Antithymocyte globulin                                                         10 (22.7)     7 (25.0)            3 (18.8)         0.72
  **Initial maintenance therapy, n (%)**[^**b**^](#t001fn003){ref-type="table-fn"}                                                      
      Mycophenolate mofetil                                                          36 (81.8)     23 (82.1)           13 (81.3)        \>0.99
      Tacrolimus                                                                     35 (79.5)     24 (85.7)           11 (68.8)        0.25
      Steroids                                                                       34 (77.3)     21 (75.0)           13 (81.3)        0.72
      Cyclosporine                                                                   6 (13.6)      2 (7.1)             4 (25.0)         0.17
      mTOR inhibitors                                                                5 (11.4)      2 (7.1)             3 (18.8)         0.34
  **CMV prophylaxis, n (%)**                                                         24 (54.5)     12 (42.9)           12 (75.0)        0.039
      ≤3 months[^c^](#t001fn004){ref-type="table-fn"}                                18 (75.0)     10 (83.3)           8 (66.7)         0.64
      ≥6 months[^c^](#t001fn004){ref-type="table-fn"}                                6 (25.0)      2 (16.7)            4 (33.3)         

Abbreviations: D-, negative donor; D+, positive donor; R-, negative recipient; R+, positive recipient; mTOR, mammalian target of rapamycin; n, number of cases; SD, standard deviation

^a^ CMV serostatus not specified in 2 patients

^b^ May have had more than 1 initial maintenance

^c^ Percentages calculated for patients with CMV prophylaxis

Based on sequence analysis, 12 out of 44 (27%) patients showed CMV DRM by Sanger sequencing, while 16 patients (36%) showed mutations by NGS ([Table 2](#pone.0219701.t002){ref-type="table"}). All the 16 patients had mutations in the UL97 gene and in addition, two patients had one mutation each in the UL54 gene (D413N and P522A). The NGS identified six low abundance resistance mutations that had not been reported by Sanger sequencing, since they were presented in \<20% of the viral population. Patients 8 and 16 showed two mutations in UL97 (C592G + M460V and L595W + A594V respectively); in both cases. In these two patients, M460V and A594V, respectively, were only detected by NGS. These six mutations were reproducibly detected at similar levels in two independent sequencing experiments. All the DRM identified by Sanger were also identified by NGS. The lowest depth coverage obtained related to a resistance mutation was 7% of the viral subpopulations.

10.1371/journal.pone.0219701.t002

###### Detection of cytomegalovirus drug resistance mutations in the UL97 and UL54 genes by Sanger and next-generation sequencing.

![](pone.0219701.t002){#pone.0219701.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PATIENT   SANGER *UL97*   NGS (Coverage %) *UL97*   GCV[^a^](#t002fn001){ref-type="table-fn"}\   SANGER *UL54*   NGS Coverage % *UL54*   GCV/FOS/CDV[^a^](#t002fn001){ref-type="table-fn"} RATIO
                                                      RATIO                                                                                
  --------- --------------- ------------------------- -------------------------------------------- --------------- ----------------------- ---------------------------------------------------------
  1                         L595S (15%)               9.2                                                                                   

  2                         M460V (19%)               8.3                                                                                   

  3         A594V           A594V (20%)               8.3                                                                                   

  4          M460V          M460V (29%)               8.3                                                                                   

  5                         M460V (19%)               8.3                                                                                   

  6                         L595S (14%)               9.2                                                                                   

  7         L595S           L595S (20%)               9.2                                                                                   

  8         C592G           C592G+M460V (26%/14%)     2.9/8.3                                                                               

  9         H520Q           H520Q (30%)               10                                                                                    

  10        M460V           M460V (31%)               8.3                                          P522A           P522A (22%)             3/1/4.1

  11        L595S           L595S (20%)               9.2                                                                                  

  12        M460V           M460V (26%)               8.3                                                                                  

  13        M460I           M460I (31%)               5                                            D413A           D413A (24%)             6.5/0.8/11

  14        A594P           A594P (31%)               3                                                                                     

  15        L595S           L595S (23%)               9.2                                                                                   

  16        L595W           L595W+A594V (21%/7%)      5.1/8.3                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^IC~50~ of mutant /IC~50~ of wild type. If IC~50~ \>5 the resistance was considered of high grade while an IC~50~ \<3 was considered as low-grade resistance.

GCV: ganciclovir, FOS: foscarnet, CDV:cidofovir

The detection of mutations by NGS allowed the differentiation and comparison of the patients with and without mutations (Tables [1](#pone.0219701.t001){ref-type="table"} and [3](#pone.0219701.t003){ref-type="table"}). The presence of mutations was more frequent in lung transplant recipients (p = 0.050) and in patients receiving prophylaxis (42.9% *vs*. 75%, p = 0.039), regardless of its duration. The median time between transplantation and suspicion of resistance was significantly longer in the group with DRM (211.5 days \[87.5; 285.0\] vs 108.5 days \[43.5; 201.5\] p = 0.038) as was the median treatment duration before suspicion of resistance (41.5 days \[18.0; 75.5\] vs 16.0 days \[14.5; 22.5\] (p = 0.024). At the time of suspicion of resistance, 75% of patients without mutations were receiving therapy for asymptomatic CMV replication and 50% of patients with DRM were receiving treatment for CMV disease. CMV disease was diagnosed in 54.5% of patients. However, biopsy confirmation was achieved in only 3 patients. All the patients were receiving standard GCV/VGCV doses at the time of suspicion of resistance and in the absence of DRM study results the treatment was empirically modified accordingly. In patients with a DRM, mTORi was added or changed empirically (50%, p = 0.009). No statistically significant differences were observed between the patients with and without mutations in relation to outcome at 3 months ([Table 3](#pone.0219701.t003){ref-type="table"}).

10.1371/journal.pone.0219701.t003

###### Data at the onset and beyond the suspicion of resistance.

![](pone.0219701.t003){#pone.0219701.t003g}

  Variables                                                                                Overall                  Without Mutations       With Mutations           P value
  ---------------------------------------------------------------------------------------- ------------------------ ----------------------- ------------------------ ---------
  **Time interval between transplantation and suspicion, median (IQR), days**              116.5 (60.0; 232.5)      108.5 (43.5; 201.5)     211.5 (87.5; 285.0)      0.038
  **Days of therapy before suspicion, median (IQR)**                                       20.0 (15.0; 48.0)        16.0 (14.5; 22.5)       41.5 (18.0;75.5)         0.024
  **Treatment at the time of suspicion, n (%)**                                                                                                                      
      Preemptive treatment                                                                 28 (63.5)                21 (75.0)               7 (43.8)                 0.038
      Disease treatment                                                                    15 (34.1)                7 (25.0)                8 (50.0)                 0.092
      Prophylaxis                                                                          1 (2.3)                  0 (0)                   1 (6.3)                  0.36
  **CMV viral load at the time of suspicion, median (IQR), copies/ml**                     11,304 (3,521; 64,105)   7,088 (2,415; 47,555)   36,236 (9,609; 65,247)   0.17
  **Symptoms at the time of suspicion, n (%)**[^**a**^](#t003fn002){ref-type="table-fn"}   24 (54.5)                14 (50)                 10 (62)                  0.53
      Viral syndrome[^b^](#t003fn003){ref-type="table-fn"}                                 13 (29.5)                10 (35.7)               3 (18.8)                 0.31
      Gastrointestinal disease[^c^](#t003fn004){ref-type="table-fn"}                       8 (18.2)                 3 (10.7)                5 (31.3)                 0.12
      Pneumonitis                                                                          4 (9.1)                  2 (7.1)                 2 (12.5)                 0.61
      Retinitis                                                                            2 (4.5)                  2 (7.1)                 0 (0)                    0.53
      Hepatitis                                                                            1 (2.3)                  1 (3.6)                 0 (0)                    \>0.99
      Disseminated (\>1 end organ)                                                         1 (2.3)                  0 (0)                   1 (6.3)                  0.36
  **Therapeutic strategy on suspicion, n (%)**[^**d**^](#t003fn005){ref-type="table-fn"}                                                                             
      Increase GCV/VGC dose                                                                15 (34.1)                10 (35.7)               5 (31.3)                 0.764
      Continue with standard GCV/VGC[^e^](#t003fn006){ref-type="table-fn"} dose            18 (40.9)                13 (46.4)               5 (31.3)                 0.325
      Decreased immunosuppression                                                          12 (27.3)                6 (21.4)                6 37.5)                  0.303
      Switch or add mTOR inhibitors                                                        11 (25.0)                3 (10.7)                8 (50.0)                 0.009
      Switch or add foscanet                                                               8 (18.2)                 3 (10.7)                5 (31.3)                 0.12
  **Outcome (at 3 months)**                                                                                                                                          
      Viral response                                                                                                                                                 
          Total suppression of CMV replication                                             25 (56.8)                18 (64.3)               7 (43.8)                 0.186
          Incomplete suppression                                                           19 (43.2)                10 (35.7)               9 (56.3)                 0.156
      **Final outcome**[^**f**^](#t003fn007){ref-type="table-fn"}                                                                                                    
          Graft rejection                                                                  5 (11.9)                 3 (11.1)                2 (13.3)                 \>0.99
          Death                                                                            5 (11.9)                 3 (11.1)                2 (13.3)                 \>0.99

Abbreviations: IQR, interquartile range; mTOR, mammalian target of rapamycin; n, number of case

^a^ May have had more than 1 symptom at the time of suspicion

^b^ Viral syndrome: fever \>38°C(for at least 2 days in a 4 day period) associated with leucopenia, thrombocytopenia or increase in transaminases

^c^ Gastrointestinal disease include: colitis, gastritis

^d^ May have had more than 1 therapeutic strategy on suspicion

^e^ Continue with standard prophylactic or treatment dose of GCV/VGC

^f^Final outcome not specified in 2 patients

[Table 4](#pone.0219701.t004){ref-type="table"} shows the clinical and virological data of the SOT recipients with known CMV DRM. Of the variables associated with the presence of resistance mutations in the univariate logistic regression analyses ([S2 Text](#pone.0219701.s002){ref-type="supplementary-material"}. [S2 Table](#pone.0219701.s005){ref-type="supplementary-material"}), treatment duration before suspicion of resistance was the only factor independently associated with the presence of mutations in the multivariate analysis (log-transformed scale, OR 2.24, 95% CI 1.03 to 4.87). The area under the ROC curve was 0.71 (95% CI 0.53 to 0.88) for the final model of mutations ([S1 Fig](#pone.0219701.s006){ref-type="supplementary-material"}).

10.1371/journal.pone.0219701.t004

###### Clinical and virological data in solid organ transplant recipients with cytomegalovirus resistance mutations.

![](pone.0219701.t004){#pone.0219701.t004g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \    Type of Transplant (CMV serostatus)   Induction therapy   Prophylaxis (months)   Treatment on suspicion\                                      Symptomatic on suspicion of resistance                                    *UL97/UL54* DRM (Days post-TX)   CMV viral [^b^](#t004fn003){ref-type="table-fn"}\   Therapeutic adaptation on suspicion of resistance   Virological and/or clinical outcome [^c^](#t004fn004){ref-type="table-fn"}
                                                                                        of resistance[^a^](#t004fn002){ref-type="table-fn"} (Days)                                                                                                              (copies/ml)                                                                                             
  ---- ------------------------------------- ------------------- ---------------------- ------------------------------------------------------------ ------------------------------------------------------------------------- -------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------------------------
  1    Kidney D+/R-                          ATG                 3 M                    Disease VGC 900mg/12h (16)                                   Suspected colitis                                                         L595S (91)                       4.180                                               GCV/VGC increased mTORi                             IS.

  2    Kidney D+/R+                          Basiliximab         No                     Preemptive treatment VGC 450mg/12h (15)                      No                                                                        M460V (68)                       55.253                                              GCV/VGC increased                                   CS.Total resolution

  3    Liver D+/R-                           No                  No                     Preemptive treatment VGC 450mg/12h(15)                       No                                                                        A594V 63)                        9.300                                               GCV/VGC increased ISP decreased                     IS. Cell-mediated rejection

  4    Liver D+/R-                           No                  3M                     Disease VGC 450mg/12h(15)                                    Viral syndrome[^d^](#t004fn005){ref-type="table-fn"}, Suspected colitis   M460V (203)                      3.849                                               ISP decreased Continue with GCV/VGCV                CS.Total resolution

  5    Kidney D+/R+                          Basiliximab         1M                     Disease VGC 450mg/12h(84)                                    Suspected gastritis                                                       M460V (235)                      11.234                                              ISP decreased GCV/VGC increased mTORi               CS. Total resolution

  6    Kidney D+/R+                          ATG                 No                     Disease VGC 450mg/12h(67)                                    Viral syndrome [^d^](#t004fn005){ref-type="table-fn"} Suspected colitis   L595S (58)                       114.167                                             GCV/VGC increased                                   CS.Total resolution

  7    Heart D+/R-                           No                  3M                     Disease VGC 100mg/12h (20)                                   Viral syndrome [^d^](#t004fn005){ref-type="table-fn"}                     L595S (350)                      154.486                                             GCV/VGC increased                                   IS

  8    Kidney D+/R-                          ATG                 3M                     Disease VGC 450mg/12h(61)                                    Suspected colitis                                                         C592G+M460V (102)                11.605                                              GCV/VGC increased. mTORi                            IS

  9    Lung D+/R-                            No                  12M                    Prophylaxis VGC 900mg/24h(38)                                Confirmed pneumonitis                                                     H520Q (210)                      33.772                                              ISP Decreased. FOS. mTORi                           CS.Total resolution

  10   Lung D+/R-                            No                  12M                    Preemptive treatment VGC 900mg/12h(96)                       No                                                                        M460V/P522A (335)                68.494                                              ISP Decreased .FOS. mTORi                           IS

  11   Lung D+/R-                            No                  6M                     Preemptive treatment VGC 900mg/12h(26)                       No                                                                        L595S (210)                      38.700                                              ISP Decreased .FOS. mTORi                           CS.Total resolution

  12   Liver D+/R-                           No                  No                     Disease VGC 450mg/12h (45)                                   Confirmed pneumonitis and retinitis                                       M460V (340)                      9.919                                               Continue with GCV/VGCV. mTORi                       IS. Death

  13   Lung D+/R-                            Basiliximab         12M                    Preemptive treatment VGC 450mg/12h(231)                      No                                                                        M460I/D413N (400)                62.000                                              GCV/VGC increased. Leflunomide                      IS. Cell-mediated rejection

  14   Heart D+/R-                           Basiliximab         1M                     Preemptive treatment VGC 450mg/12h(113)                      Viral syndrome[^d^](#t004fn005){ref-type="table-fn"}                      A594P (331)                      59.879                                              Continue with GCV/VGCV. Maribavir                   IS

  15   Kidney D+/R-                          No                  1M                     Disease VGC 450mg/12h(28)                                    Viral syndrome[^c^](#t004fn004){ref-type="table-fn"} Suspected colitis    L595S (112)                      721.000                                             Switch to FOS                                       IS. Death

  16   Heart D+/R-                           Basiliximab         2M                     Preemptive treatment VGC 900mg/12h(51)                       Viral syndrome[^d^](#t004fn005){ref-type="table-fn"}                      L595W+A594V (84)                 4.120                                               GCV/VGC increased. FOS. mTORi                       CS.Total resolution
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CMV, cytomegalovirus; D, donor; R, recipient; TX, transplantation; GCV, ganciclovir; VGC, valganciclovir; FOS, foscarnet, CDV, cidofovir; ATG, antithymocyte globulin; ISP, immunosuppression; IS, incomplete suppression; CS, total supression of CMV replication

^a^Drug/doses

^b^CMV viral load on suspicion of resistance

^c^Virological and clinical outcomes at 3 months

^d^Presence of fever \>38°C (for at least 2 days in a 4 day period) associated with leucopenia, thrombocytopenia or an increase in transaminases

Discussion {#sec013}
==========

Drug-resistant CMV infection is an important emerging problem in SOT recipients. However, it may be underdiagnosed since mutation analysis is not routinely performed and the current gold-standard Sanger sequencing method lacks sufficient sensitivity \[[@pone.0219701.ref001]\]. In the present study, a NGS was compared with Sanger sequencing to identify mutations associated with resistance in SOT patients with suspicion of resistance. Among the 44 patients recruited, 14 DRM were detected by Sanger in 12 patients (27%) and 20 DRM were detected with NGS in 16 patients (36%), respectively. NGS showed a higher sensitivity for the detection of mutations present in \<20% of the population sequenced which were not found by Sanger sequencing. Univariate analysis of the clinical data revealed that the presence of DRM detected by NGS was associated with lung transplantation (p = 0.050), prophylactic treatment (p = 0.039), a higher mean time between transplantation and suspicion of resistance (p = 0.038) and longer treatment duration with GCV or VGCV before suspicion (p = 0.024). However, the latter was the only factor independently associated with the presence of resistance mutations in the multivariate analysis.

Several aspects differentiate the present stydy from other similar studies in the field reported to date, and these aspects can be summarized as follows:NGS was addressed to the *UL97* and *UL54* genes, a relatively high number of patients, undergoing different solid organ transplanted were studied, and associated risk factors were also evaluated.

The current gold standard for the genotypic detection of CMV drug resistance is Sanger sequencing of the *UL97* and *UL54* genes. However, this technique cannot detect viral variants that represent \< 20% of the viral population \[[@pone.0219701.ref009], [@pone.0219701.ref010]\]. This lack of sensitivity can lead to continued administration of an antiviral to which resistance has developed and the subsequent expansion of initially minority populations of resistant variants leading to the development of treatment failure, increased morbidity and shortened graft survival. On the other hand, modifications in therapy following the identification of GCV resistance is associated with more rapid viral clearance, further emphasising the importance of timely detection of resistance \[[@pone.0219701.ref007], [@pone.0219701.ref011], [@pone.0219701.ref012]\]. Recent studies have shown that NGS methods can provide new insights into viral diversity and in the detection of low-abundance variants by the analysis of thousands of amplicons in a single experiment \[[@pone.0219701.ref010], [@pone.0219701.ref025]\]. However, so far, only a few studies have focused on CMV-resistant mutants. Most studies have included few patients and only some cover the UL97 gene \[[@pone.0219701.ref011], [@pone.0219701.ref012]\]. An exception to this is the study by Sahoo et al which evaluated DRM in both of the genes involved using NGS in a considerable number of specimens \[[@pone.0219701.ref010]\]. However, this study did not include an analysis of clinical factors. In our study, NGS identified six low abundance resistant mutations that had not been reported by Sanger sequencing, thus suggesting that NGS is more sensitive than Sanger since the use of high throughput sequencing allowed the detection of viral subpopulations with a prevalence of 7%. All six mutations were located in the *UL97* gene and showed high-level resistance to GCV \[[@pone.0219701.ref026], [@pone.0219701.ref027]\]. In addition, two of these six DRM identified were present as mixed mutations in two patients which may have important implications in patient management. Therefore, studies with prospective monitoring of the abundance of such mutations over time and an assessment of their association with virologic failure are necessary. *UL54* DNA polymerase mutations are typically selected after prolonged GCV exposure and were revealed in 2 lung transplant patients who had received a longer prophylaxis and preemptive treatment \[[@pone.0219701.ref028], [@pone.0219701.ref029]\]. However, compared to Sanger sequencing NGS did not improve the detection sensitivity of DRM in the *UL54* gene in concordance with the results of Sahoo et al \[[@pone.0219701.ref010]\].

In the present study longer treatment duration with antivirals before suspicion of resistance was identified as a risk factor associated with DRM (p = 0.24)\[[@pone.0219701.ref001], [@pone.0219701.ref002]\], and is considered a major factor in the selection and emergence of resistance. Lung transplantation showed the highest incidence of DRM. It is important to note that 4 out of 5 lung transplant patients in our study presented DRM and all had received lengthy preemptive treatment and antiviral prophylaxis \[[@pone.0219701.ref029], [@pone.0219701.ref030]\]. Moreover, the presence of DRM was more frequent among transplant recipients who had received prophylaxis (p = 0.039). Nonetheless, other factors may have also contributed to this finding. The interdependence of host, virus and antiviral therapy is likely associated with the development of DRM \[[@pone.0219701.ref031]\]. In fact, all the patients included in this study had one or more known risk factors predisposing to DRM \[[@pone.0219701.ref001], [@pone.0219701.ref002]\]. Therefore, according to current consensus guidelines genotypic testing confirmation should be done irrespective of any exclusion criteria whenever antiviral resistance is suspected \[[@pone.0219701.ref005], [@pone.0219701.ref006]\], since resistance might otherwise be underestimated similar to what has been described in previous reports \[[@pone.0219701.ref032]\]. In the present study, DRM were found in unusual situations, such as during prophylaxis in one patient and in 3 patients with CMV D+/R+ serostatus.

Previous studies have reported antiviral resistance to be associated with increased attributable morbidity and mortality \[[@pone.0219701.ref002]\]. This was not found in the present study, likely because patients were only clinically followed during the first three months. Moreover, clinicians were unaware of the presence of DRM in real time, and therefore, treatment was empirically modified. Thus, we were unable to evaluate the outcome of the patients according to Sanger or NGS sequencing results. This should be addressed in future studies.

In our cohort, 64% of the patients suspected of having resistance to antivirals did not present DRM. Therefore, as suggested previously other factors might contribute to treatment failure \[[@pone.0219701.ref033]\]. Emphasis should be given to prioritizing the optimization of host factors rather than switching antiviral medications, thereby adjusting immunosuppressive therapy whenever possible. Additionally, blood GCV levels were not available and were not performed during the clinical care of the patients studied, and thus, sub-therapeutic GCV levels may be a possible cause of non-response to treatment in some patients. On the other hand, a recent study of serial specimens received for genotypic testing showed that the first specimen tested negative for DRM in more than half of the patients, although about two-thirds eventually became positive on repeated testing \[[@pone.0219701.ref004]\]. It could therefore be suggested that patients without DRM but with suspected criteria of resistance should be closely monitored and new samples should be studied for viral mutations.

Our study has limitations regarding the modest sample size and the lack of balance among groups although it does reflect real life in a nation-wide cohort study. Our results should be confirmed in larger and better balanced cohorts. Another limitation is that the analysis of GCV resistance of the mutations was performed only when there was suspicion; Nonetheless, these patients represented the group with the highest risk for antiviral resistant CMV.

In summary, the development of DRM may be a direct effect of a longer duration of antiviral treatment, and thus, the implementation of effective CMV prevention strategies that minimise drug exposure could lead to lower resistance rates. Although the clinical risk factors for drug resistance have been relatively well defined, genotypic testing should be performed in all patients with suspected criteria of resistance. Despite the lack of standardized protocols and the complexity of the bioinformatics analysis for the use of NGS in routine clinical practice, the results of this study suggests that NGS technology improves the genotypic diagnosis of DRM, fundamentally in low-abundance variants and mixed populations allowing early detection of the emergence of CMV-resistant strains and subsequent targeted adjustment of therapy.
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